PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Clinical Trial

Official title:

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00690066
• Other study ID #: 901
• Status: Completed
• Phase: Phase 2
• Start date: June 11, 2008
• Est. completion date: December 19, 2011

Study information

• Verified date: December 2021
• Source: Mesoblast, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.

Description:

Diabetes mellitus refers to disorders in which the body has trouble controlling its blood glucose levels. There are two main types of diabetes: type 1 and type 2. Type 1 diabetes mellitus (T1DM), which is being studied in this trial, is an autoimmune disorder in which the body's own immune system attacks and destroys the cells that make insulin. These cells are called beta cells. As beta cells are destroyed, less insulin can be made. This causes blood sugar levels to increase above normal and can cause life-threatening hypo- and hyper-glycemic reactions. For this reason, people with type 1 diabetes must take insulin to help control their blood sugar levels. Over time, poorly controlled diabetes can lead to a variety of serious health conditions, including heart disease, stroke, blindness, amputations, kidney disease, and nerve damage. Insulin is the primary method of controlling diabetes by regulating blood glucose levels, but it may not reverse or prevent disease progression. The active ingredient in PROCHYMAL® is adult human mesenchymal stem cells (MSCs). MSCs have been shown to interact with the immune cells in the body, reducing inflammation and assisting in tissue repair. This study will help determine whether MSCs can protect normal pancreatic tissue from autoimmune attack and repair damaged pancreatic tissue, leading to an increase in insulin production and decrease in circulating blood glucose. The characteristics and biologic activity of PROCHYMAL®, along with a good safety profile in human trials to date, suggest that PROCHYMAL® may be a good candidate for addressing Type 1 Diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: December 19, 2011
• Est. primary completion date: December 12, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 35 Years

Eligibility

Inclusion Criteria:

• Participant must have a diagnosis of type 1 diabetes mellitus based on the American Diabetes Association (ADA) criteria.

• Participant must be screened between 2 and 20 weeks from initial T1DM diagnosis

• Participants must be between the ages of 12 and 35 (inclusive).

• Participant must have at least one diabetes-related autoantibody present (either GAD or IA-2).

• Participant must have some beta cell function as determined by C-peptide testing (at least 0.2 pmol/mL (0.6 ng/mL) during MMTT.

• Participants must be willing to comply with "intensive diabetes management" as directed by the Investigator with the goal of maintaining blood glucose as close to normal as possible (i.e., glycosylated hemoglobin A1c (HbA1c) value of = 7.0%).

• Participants must be willing to comply with the schedule of study visits and protocol requirements.

Exclusion Criteria:

• Participant has Body Mass Index (BMI) = 30.

• Participant has evidence of retinopathy at baseline.

• Participant has abnormally high lipid levels.

• Participant has abnormal blood pressure.

• Participant has an abnormal serum creatinine.

• Participant has evidence of clinically significant proteinuria.

• Participant has diabetic ketoacidosis.

• Participant is being treated for a severe active infection of any type.

• A female participant who is breast-feeding, pregnant, or intends to become pregnant during the study.

• Participant with clinically relevant uncontrolled medical condition not associated with diabetes (e.g. hematologic, renal, hepatic, neurologic, cardiac, or respiratory).

• Participant has received an investigational drug (not approved by the FDA) for any indication 30 days prior to the screening visit.

• Participant is allergic to bovine or porcine products.

• Participant has evidence of active malignancy or prior history of active malignancy that has not been in remission for at least 5 years.

• Participant has any medical condition, which in the opinion of the Investigator, rendered his/her participation in this study unsuitable.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Insulin-Dependent
• Diabetes Mellitus, Type 1
• Juvenile Diabetes
• Type 1 Diabetes
• Type 1 Diabetes Mellitus

Intervention

Drug:
• PROCHYMAL®
Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
• Placebo
Intravenous infusion of excipients of PROCHYMAL®

Locations

Country	Name	City	State
United States	AM Diabetes & Endocrinology Center	Bartlett	Tennessee
United States	University of Alabama, Division of Endocrinology & Metabolism	Birmingham	Alabama
United States	Cumberland Valley Endocrinology	Carlisle	Pennsylvania
United States	University of North Carolina Diabetes Care Center	Chapel Hill	North Carolina
United States	American Health Research, Inc.	Charlotte	North Carolina
United States	The Lindner Clinical Trial Center	Cincinnati	Ohio
United States	The University of Texas Southwestern Medical Center	Dallas	Texas
United States	Providence Health Partners - Center for Clinical Research	Dayton	Ohio
United States	University of Florida	Gainesville	Florida
United States	Desert Endocrinology CRC	Henderson	Nevada
United States	Scripps Whittier Diabetes Institute	La Jolla	California
United States	Nevada Alliance Against Diabetes	Las Vegas	Nevada
United States	University of Kentucky	Lexington	Kentucky
United States	University of Wisconsin Health- West Clinic	Madison	Wisconsin
United States	Diabetes Research Institute	Miami	Florida
United States	Clinical and Transitional Science Institute	Milwaukee	Wisconsin
United States	University of Minnesota	Minneapolis	Minnesota
United States	The Strelitz Diabetes Center, Eastern VA Medical School	Norfolk	Virginia
United States	Optimum Clinical Research, Inc.	Salt Lake City	Utah
United States	Stanford University	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Mesoblast, Inc.	Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	C-peptide area under the concentration curve (AUC) response (MMTT)		1 year
Secondary	Peak C-peptide response (MMTT)		2 years
Secondary	Basal C-peptide response		2 years
Secondary	Total daily insulin dose (units/kg)		2 years
Secondary	Glycosylated hemoglobin (HbA1c) levels		2 years
Secondary	Number of severe and documented hypoglycemic events		2 years
Secondary	Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies		2 years